ATYR aTYR PHARMA INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1339970 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.1%
TTM net income YoY-15.8%
TTM EPS YoY7.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-40,856.3%
Net margin-39,009.5%
FCF margin-32,664.7%
EBITDA margin-40,506.8%
Returns
ROE-107.8%
ROA-78.1%
ROIC (approx.)-106.0%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets27.6%
Debt / equity0.00x
Current ratio5.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-12.8%
Payout ratio—
Capex / revenue40.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $190,000 | $235,000 | $353,000 | $10.39M | $0 |
| R&D expense | $60.22M | $54.37M | $42.29M | $42.81M | $23.26M |
| SG&A expense | $17.60M | $13.78M | $12.98M | $13.98M | $10.75M |
| Operating income | -$77.63M | -$67.91M | -$54.92M | -$46.40M | -$34.02M |
| Pretax income | -$74.12M | -$64.02M | -$50.40M | -$45.34M | -$33.77M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$74.12M | -$64.02M | -$50.39M | -$45.34M | -$33.77M |
| EBITDA | -$76.96M | -$67.21M | -$54.33M | -$46.17M | -$33.54M |
| EPS (basic) | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 |
| EPS (diluted) | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 |
| Weighted avg. shares (diluted) | 92.99M | 74.26M | 53.61M | 28.42M | 19.08M |
| Balance sheet | |||||
| Cash & equivalents | $10.74M | $11.05M | $22.54M | $9.98M | $2.34M |
| Short-term investments | $67.94M | $61.07M | $75.62M | $56.16M | $105.58M |
| Current assets | $80.24M | $81.95M | $102.99M | $80.87M | $113.57M |
| PP&E, net | $4.26M | $4.85M | $5.53M | $3.06M | $543,000 |
| Total assets | $93.00M | $96.83M | $120.65M | $95.79M | $115.54M |
| Current liabilities | $15.15M | $14.97M | $16.42M | $13.86M | $6.01M |
| Total liabilities | $25.71M | $27.00M | $30.18M | $24.50M | $6.41M |
| Shareholders' equity | $67.48M | $70.02M | $90.66M | $71.46M | $109.30M |
| Shares outstanding | 2.45M | 84.04M | 63.29M | 29.50M | 27.79M |
| Cash flow statement | |||||
| Operating cash flow | -$61.99M | -$69.12M | -$33.22M | -$41.89M | -$33.08M |
| Capital expenditure | $77,000 | $65,000 | $4.21M | $1.64M | $192,000 |
| Free cash flow | -$62.06M | -$69.18M | -$37.44M | -$43.53M | -$33.27M |
| Investing cash flow | -$5.05M | $17.23M | -$20.13M | $47.24M | -$91.57M |
| Financing cash flow | $66.01M | $39.86M | $66.23M | $5.45M | $110.03M |
| Depreciation & amortization | $664,000 | $708,000 | $592,000 | $232,000 | $475,000 |
| Stock-based compensation | $5.00M | $2.99M | $2.60M | $2.15M | $1.61M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.